|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Candesartan#Adverse Reactions]] |
| {{Candesartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| ===Clinical Studies Experience===
| |
| | |
| Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
| |
| | |
| ====Adult Hypertension====
| |
| | |
| ATACAND has been evaluated for safety in more than 3600 patients/subjects, including more than 3200 patients treated for hypertension. About 600 of these patients were studied for at least 6 months and about 200 for at least 1 year. In general, treatment with ATACAND was well tolerated. The overall incidence of adverse events reported with ATACAND was similar to placebo.
| |
| | |
| The rate of withdrawals due to adverse events in all trials in patients (7510 total) was 3.3% (ie, 108 of 3260) of patients treated with ATACAND as monotherapy and 3.5% (ie, 39 of 1106) of patients treated with placebo. In placebo-controlled trials, discontinuation of therapy due to clinical adverse events occurred in 2.4% (ie, 57 of 2350) of patients treated with ATACAND and 3.4% (ie, 35 of 1027) of patients treated with placebo.
| |
| | |
| The most common reasons for discontinuation of therapy with ATACAND were headache (0.6%) and dizziness (0.3%).
| |
| | |
| The adverse events that occurred in placebo-controlled clinical trials in at least 1% of patients treated with ATACAND and at a higher incidence in candesartan cilexetil (n = 2350) than placebo (n = 1027) patients included back pain (3% vs. 2%), dizziness (4% vs. 3%), upper respiratory tract infection (6% vs. 4%), pharyngitis (2% vs. 1%), and rhinitis (2% vs. 1%).
| |
| | |
| ====Pediatric Hypertension====
| |
| | |
| Among children in clinical studies, 1 in 93 children age 1 to < 6 and 3 in 240 age 6 to < 17 experienced worsening renal disease. The association between candesartan and exacerbation of the underlying condition could not be excluded.
| |
| | |
| ====Heart Failure====
| |
| | |
| The adverse event profile of ATACAND in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM program, comparing ATACAND in total daily doses up to 32 mg once daily (n=3803) with placebo (n=3796), 21.0% of patients discontinued ATACAND for adverse events vs. 16.1% of placebo patients.
| |
| | |
| ===Postmarketing Experience===
| |
| | |
| The following adverse reactions were identified during post-approval use of ATACAND. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
| |
| | |
| The following have been very rarely reported in post-marketing experience:
| |
| | |
| '''Digestive''': Abnormal hepatic function and hepatitis.
| |
| | |
| '''Hematologic''': [[Neutropenia]], [[leukopenia]], and [[agranulocytosis]].
| |
| '''Immunologic''': [[Angioedema]]
| |
| '''Metabolic and Nutritional Disorders''': [[Hyperkalemia]], [[hyponatremia]].
| |
| '''Respiratory system disorders''': [[Cough]]
| |
| '''Skin and Appendages Disorders''': [[Pruritus]], [[rash]] and [[urticaria]].
| |
| Rare reports of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ATACAND (CANDESARTAN CILEXETIL) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a73e1339-9643-4eea-2cbe-e879c88fb50e | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Angiotensin II receptor antagonists}}
| |
| | |
| [[Category:Angiotensin II receptor antagonists]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Ethers]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |